BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1592363)

  • 21. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer.
    Lundin J; Nordling S; von Boguslawsky K; Roberts PJ; Haglund C
    Anticancer Res; 1995; 15(6B):2659-68. PubMed ID: 8669843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms.
    Steck K; el-Naggar AK
    Cytometry; 1994 Nov; 17(3):258-65. PubMed ID: 7851161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
    López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
    Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
    Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between Ki-67 index and S-phase fraction on fine-needle aspiration samples from breast carcinoma.
    Bozzetti C; Nizzoli R; Camisa R; Guazzi A; Ceci G; Cocconi G; Mazzini G; Naldi N
    Cancer; 1997 Oct; 81(5):287-92. PubMed ID: 9349516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
    Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
    Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell proliferation in childhood acute leukemia. Comparison of Ki-67 and proliferating cell nuclear antigen immunocytochemical and DNA flow cytometric analysis.
    Ito M; Tsurusawa M; Zha Z; Kawai S; Takasaki Y; Fujimoto T
    Cancer; 1992 Apr; 69(8):2176-82. PubMed ID: 1347483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
    Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
    Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
    Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
    Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual parameter analysis of myeloma cells by flow cytometry. DNA content of cells containing monotypic cytoplasmic immunoglobulin.
    Chan CS; Wormsley SB; Peter JB; Schechter GP
    Am J Clin Pathol; 1989 Jan; 91(1):12-7. PubMed ID: 2910012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry.
    Dawson AE; Norton JA; Weinberg DS
    Am J Pathol; 1990 May; 136(5):1115-24. PubMed ID: 1972000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67.
    Lokhorst HM; Boom SE; Terpstra W; Roholl P; Gerdes J; Bast BJ
    Br J Haematol; 1988 Aug; 69(4):477-81. PubMed ID: 3044442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
    Niemöller K; Jakob C; Heider U; Zavrski I; Eucker J; Kaufmann O; Possinger K; Sezer O
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):234-8. PubMed ID: 12700896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.
    Trendle MC; Leong T; Kyle RA; Katzmann JA; Oken MM; Kay NE; Van Ness BG; Greipp PR
    Am J Hematol; 1999 Aug; 61(4):232-7. PubMed ID: 10440908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.